Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
39 participants
OBSERVATIONAL
1998-07-07
2014-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with rheumatoid arthritis and their family members may be eligible for this study.
Participants with RA who have a brother or sister with RA will undergo the following procedures:
* Review of their medical records
* Medical history
* Examination of the joints
* Hand X-rays
* Blood tests
Participants who 1) do not have RA but who have a relative with the disease, or 2) have RA and a relative other than a brother or sister who has the disease will provide a blood sample or a buccal (cheek) cell sample. Cheek cells are obtained by swishing a small amount of mouthwash in the mouth or by lightly bushing the inside of the cheek with a swab or brush.
The samples will be tested for rheumatoid factor, DNA studies, and HLA type (a blood type found on white blood cells). Certain HLA types have been associated with an increased risk or severity of RA.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inflammatory Diseases Section of the Intramural Research Program of NHGRI\] has joined with
several extramural centers to form the North American Rheumatoid Arthritis Consortium
(NARAC). The Consortium intends to identify and obtain clinical specimens on a total of 1000
sibling pairs with rheumatoid arthritis; up to 100 sibling pairs will be recruited at the Clinical
Center. Samples from parents and other family members will also be obtained, where
appropriate. Rheumatoid factors, HLA-DR typings, and hand films will be obtained on all
sibling pairs. In addition, DNA will be extracted from peripheral blood or buccal scrapings. The
DNA from all 1000 sibling pairs will be typed for a set of approximately 350 genetic markers in
order to identify chromosomal regions likely to harbor genes conferring susceptibility to
rheumatoid arthritis. For those chromosomal regions that are positive in this initial screen,
families will be genotyped for additional markers to define disease-associated haplotypes, and high density single nucleotide polymorphism (SNP) analysis will be conducted to narrow the regions of interest. Candidate genes will be chosen from the narrowed regions of interest, and/or based on functional considerations, and will be screened for mutations in rheumatoid arthritis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
A diagnosis of rheumatoid arthritis in both sibs by the 1987 ACR criteria.
Definite bony erosions in at least one affected sibling.
Age of disease onset greater than 18 years and less than 60 years in at least one sibling.
Neither sibling has psoriasis, inflammatory bowel disease, or systemic lupus erythematosus.
BLOOD RELATIVES OF AFFECTED SIBLING PAIRS:
Age greater than 18 years.
Where possible, all other affected siblings will be invited to participate.
Where possible, both parents of affected siblings will be invited to participate.
Other relatives, both affected and unaffected, may be invited to participate if, in the opinion of the investigators, samples from these individuals would contribute important genetic information. Two cases in which this might happen are: a) extended families in which there are several affected individuals, where conventional linkage analysis might be applied; b) affected sibling pairs for which parents are unavailable, where additional siblings will provide information on parental alleles not transmitted to the affected siblings.
Exclusion Criteria
Inability to provide infomed consent.
The sole criterion for exclusion of adult blood relatives of affected sibling pairs would be inability to provide informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Human Genome Research Institute (NHGRI)
NIH
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel L Kastner, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Human Genome Research Institute (NHGRI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med. 1978 Apr 20;298(16):869-71. doi: 10.1056/NEJM197804202981602.
Lawrence RC, Hochberg MC, Kelsey JL, McDuffie FC, Medsger TA Jr, Felts WR, Shulman LE. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol. 1989 Apr;16(4):427-41.
Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990 May 3;322(18):1277-89. doi: 10.1056/NEJM199005033221805. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
98-HG-0124
Identifier Type: -
Identifier Source: secondary_id
980124
Identifier Type: -
Identifier Source: org_study_id